H
376270
vs
K
KOSPI 200
Over the past 12 months, HEM Pharma Inc has underperformed KOSPI 200, delivering a return of -5% compared to KOSPI 200's +152% growth.
Stocks Performance
376270 vs KOSPI 200
Performance Gap
376270 vs KOSPI 200
Performance By Year
376270 vs KOSPI 200
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
HEM Pharma Inc
Glance View
HEM Pharma, Inc. engages in the provision of microbiome solutions. The company is headquartered in Suwon, Gyeonggi-Do and currently employs 101 full-time employees. The company went IPO on 2024-11-05. The firm mainly operates two businesses. The customized healthcare services business mainly researching and discovery the relationship between diseases and human body’s various microbiota and beneficial substances produced by microorganisms to provide the optimal solution for individuals. The live biotherapeutic products (LBP) discovery platform service business mainly provides disease biomarker verification, disease-specific animal model design, finished drug production and microbial safety evaluation services.
